Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2)-H-Hydroxylation

dc.contributor.authorBerger, Alexander
dc.contributor.authorKnak, Talea
dc.contributor.authorKiffe-Delf, Anna-Lene
dc.contributor.authorMudrovcic, Korana
dc.contributor.authorSingh, Vinayak
dc.contributor.authorNjoroge, Mathew
dc.contributor.authorBurckhardt, Bjoern B.
dc.contributor.authorGopalswamy, Mohanraj
dc.contributor.authorLungerich, Beate
dc.contributor.authorAckermann, Lutz
dc.contributor.authorGohlke, Holger
dc.contributor.authorChibale, Kelly
dc.contributor.authorKalscheuer, Rainer
dc.contributor.authorKurz, Thomas
dc.date.accessioned2022-11-29T12:26:24Z
dc.date.available2022-11-29T12:26:24Z
dc.date.issued2022-08-10
dc.date.updated2022-08-25T11:18:05Z
dc.description.abstractThe continuous, worldwide spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) endanger the World Health Organization&rsquo;s (WHO) goal to end the global TB pandemic by the year 2035. During the past 50 years, very few new drugs have been approved by medical agencies to treat drug-resistant TB. Therefore, the development of novel antimycobacterial drug candidates to combat the threat of drug-resistant TB is urgent. In this work, we developed and optimized a total synthesis of the antimycobacterial natural flavonoid chlorflavonin by selective ruthenium(II)-catalyzed <i>ortho</i>-C(sp<sup>2</sup>)-H-hydroxylation of a substituted 3&prime;-methoxyflavonoid skeleton. We extended our methodology to synthesize a small compound library of 14 structural analogs. The new analogs were tested for their antimycobacterial in vitro activity against <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) and their cytotoxicity against various human cell lines. The most promising new analog bromflavonin exhibited improved antimycobacterial in vitro activity against the virulent H37Rv strain of <i>Mtb</i> (Minimal Inhibitory Concentrations (MIC<sub>90</sub>) = 0.78 &mu;m). In addition, we determined the chemical and metabolic stability as well as the p<i>K</i><sub>a</sub> values of chlorflavonin and bromflavonin. Furthermore, we established a quantitative structure&ndash;activity relationship model using a thermodynamic integration approach. Our computations may be used for suggesting further structural changes to develop improved derivatives.en_US
dc.identifierdoi: 10.3390/ph15080984
dc.identifier.citationPharmaceuticals 15 (8): 984 (2022)
dc.identifier.citationPharmaceuticals 15 (8): 984 (2022)
dc.identifier.urihttp://hdl.handle.net/11427/36917
dc.language.isoenen_US
dc.publisher.departmentDepartment of Chemistryen_US
dc.publisher.facultyFaculty of Scienceen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.sourcePharmaceuticalsen_US
dc.source.journalissue8en_US
dc.source.journalvolume15en_US
dc.source.pagination984en_US
dc.titleTotal Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2)-H-Hydroxylationen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pharmaceuticals-15-00984-v3.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Collections